Gradientech welcomes investment from commercial partner
The diagnostics company Gradientech today announces the collaboration with a.d.a. SRL as commercial partner for the Italian clinical microbiology market for its QuickMIC® system for rapid antibiotic susceptibility testing of positive blood cultures. Based on a strong believe in the diagnostic product, a.d.a. SRL has also decided to make an investment in Gradientech.Following the CE-IVD registration of the QuickMIC® antibiotic susceptibility testing (AST) system during 2022, the commercialisation has started in selected European markets. Italy is one of the most important markets in Europe